(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...
Closer takes a look at five vaccines you should get after you turn 50 to help protect against illness. Shingles: “The first ...
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
Researchers conducted an observational study to compare the risk for dementia associated with both the live and recombinant shingles vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback